Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity

Experimental Hematology

Volumn 41, Issue 9, 2013, Pages 799-807.e4

  Sen, Siddhartha ^a   Hassane, Duane C ^a   Corbett, Cheryl ^b   Becker, Michael W ^b   Jordan, Craig T ^b   Guzman, Monica L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CICLOPIROX; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PARTHENOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LEUKEMIA STEM CELL; MONOTHERAPY; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84883551479     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.012     Document Type: Article

References (51)

1. Ravandi F., Burnett A.K., Agura E.D., Kantarjian H.M. Progress in the treatment of acute myeloid leukemia. Cancer 2007, 110:1900-1910.
2. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
3. Estey E.H. Therapeutic options for acute myelogenous leukemia. Cancer 2001, 92:1059-1073.
4. Dick J.E., Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 2005, 82:389-396.
5. Dick J.E. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005, 1044:1-5.
6. Kikushige Y., Shima T., Takayanagi S., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
7. Majeti R., Chao M.P., Alizadeh A.A., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
8. Hosen N., Park C.Y., Tatsumi N., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:11008-11013.
9. Jordan C.T., Upchurch D., Szilvassy S.J., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
10. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
11. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
12. van Rhenen A., van Dongen G.A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
13. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
14. Guzman M.L., Rossi R.M., Neelakantan S., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
15. Neelakantan S., Nasim S., Guzman M.L., Jordan C.T., Crooks P.A. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009, 19:4346-4349.
16. Jenkins C., Hewamana S., Gilkes A., et al. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol 2008, 143:661-671.
17. Hassane D.C., Sen S., Minhajuddin M., et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010, 116:5983-5990.
18. Yip-Schneider M.T., Wu H., Hruban R.H., Lowy A.M., Crooks P.A., Schmidt C.M. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas 2013, 42:160-167.
19. Holcomb B.K., Yip-Schneider M.T., Waters J.A., Beane J.D., Crooks P.A., Schmidt C.M. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg 2012, 16:1333-1340.
20. Estabrook N.C., Chin-Sinex H., Borgmann A.J., et al. Inhibition of NF-kappaB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radic Biol Med 2011, 51:2249-2258.
21. Yip-Schneider M.T., Wu H., Njoku V., et al. Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas 2008, 37:e45-e53.
22. Walsby E.J., Pratt G., Hewamana S., et al. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Mol Cancer Ther 2010, 9:1574-1582.
23. Gao Z.W., Zhang D.L., Guo C.B. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in invitro and invivo human non-small cell lung cancer models. Curr Cancer Drug Targets 2010, 10:705-715.
24. Eberhard Y., McDermott S.P., Wang X., et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009, 114:3064-3073.
25. Balabanov S., Gontarewicz A., Ziegler P., et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007, 109:1701-1711.
26. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 2002, 99:16220-16225.
27. Lansdorp P.M., Dragowska W. Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow. J Exp Med 1992, 175:1501-1509.
28. Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991, 77:2031-2036.
29. Loewith R., Jacinto E., Wullschleger S., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10:457-468.
30. Kim D.H., Sarbassov D.D., Ali S.M., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
31. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
32. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
33. Dumont F.J., Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996, 58:373-395.
34. von Manteuffel S.R., Dennis P.B., Pullen N., Gingras A.C., Sonenberg N., Thomas G. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol 1997, 17:5426-5436.
35. Dennis P.B., Pullen N., Kozma S.C., Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 1996, 16:6242-6251.
36. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
37. Tremblay F., Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 2001, 276:38052-38060.
38. Breuleux M., Klopfenstein M., Stephan C., et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009, 8:742-753.
39. Clement P.M., Hanauske-Abel H.M., Wolff E.C., Kleinman H.K., Park M.H. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis invitro. Int J Cancer 2002, 100:491-498.
40. Park M.H. The essential role of hypusine in eukaryotic translation initiation factor 4D (eIF-4D). Purification of eIF-4D and its precursors and comparison of their activities. J Biol Chem 1989, 264:18531-18535.
41. Smit-McBride Z., Schnier J., Kaufman R.J., Hershey J.W. Protein synthesis initiation factor eIF-4D. Functional comparison of native and unhypusinated forms of the protein. J Biol Chem 1989, 264:18527-18530.
42. Park M.H., Wolff E.C., Lee Y.B., Folk J.E. Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J Biol Chem 1994, 269:27827-27832.
43. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
44. Huang S., Bjornsti M.A., Houghton P.J. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003, 2:222-232.
45. Sehgal V.N. Ciclopirox: A new topical pyrodonium antimycotic agent. A double-blind study in superficial dermatomycoses. Br J Dermatol 1976, 95:83-88.
46. Subissi A., Monti D., Togni G., Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010, 70:2133-2152.
47. Leem S.H., Park J.E., Kim I.S., Chae J.Y., Sugino A., Sunwoo Y. The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells 2003, 15:55-61.
48. Luo Y., Zhou H., Liu L., et al. The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene 2011, 30:2098-2107.
49. Kim Y., Schmidt M., Endo T., Lu D., Carson D., Schmidt-Wolf I.G. Targeting the Wnt/Beta-catenin Pathway with the Antifungal Agent Ciclopirox Olamine in a Murine Myeloma Model. InVivo 2011, 25:887-893.
50. Callens C., Coulon S., Naudin J., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207:731-750.
51. Napier I., Ponka P., Richardson D.R. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 2005, 105:1867-1874.